Accéder au contenu
Merck
Toutes les photos(1)

Documents

Y0001027

Betamethasone 17-valerate

European Pharmacopoeia (EP) Reference Standard

Synonyme(s) :

1,4-pregnadiène-11β,17α,21-triol-9α-fluoro-16β-méthyl-3,20-dione 17-valérate, 9α-fluoro-16β-méthyl-11β,17α,21-trihydroxy-1,4-pregnadiène-3,20-dione 17-valérate, 9α-fluoro-16β-méthylprednisolone 17-valérate, Betnovate

Se connecterpour consulter vos tarifs contractuels et ceux de votre entreprise/organisme
Toutes les photos(1)

About This Item

Formule empirique (notation de Hill):
C27H37FO6
Numéro CAS:
2152-44-5
Poids moléculaire :
476.58
Numéro Beilstein :
4240001
Numéro MDL:
MFCD00867446
Code UNSPSC :
41116107
ID de substance PubChem :
329831226
Nomenclature NACRES :
NA.24

Qualité

pharmaceutical primary standard

Famille d'API

betamethasone

Fabricant/nom de marque

EDQM

Application(s)

pharmaceutical (small molecule)

Format

neat

Température de stockage

2-8°C

Chaîne SMILES 

CCCCC(=O)O[C@@]1([C@@H](C)CC2C3CCC4=CC(=O)C=C[C@]4(C)[C@@]3(F)[C@@H](O)C[C@]12C)C(=O)CO

InChI

1S/C27H37FO6/c1-5-6-7-23(33)34-27(22(32)15-29)16(2)12-20-19-9-8-17-13-18(30)10-11-24(17,3)26(19,28)21(31)14-25(20,27)4/h10-11,13,16,19-21,29,31H,5-9,12,14-15H2,1-4H3/t16-,19?,20?,21-,24-,25-,26-,27-/m0/s1

Clé InChI

SNHRLVCMMWUAJD-QDHNOTTGSA-N

Vous recherchez des produits similaires ? Visite Guide de comparaison des produits

Description générale

This product is provided as delivered and specified by the issuing Pharmacopoeia. All information provided in support of this product, including SDS and any product information leaflets have been developed and issued under the Authority of the Issuing Pharmacopoeia. For further information and support please go to the website of the issuing Pharmacopoeia.

Application

Betamethasone valerate for system suitability EP Reference standard, intended for use in laboratory tests only as specifically prescribed in the European Pharmacopoeia.

Conditionnement

The product is delivered as supplied by the issuing Pharmacopoeia. For the current unit quantity, please visit the EDQM reference substance catalogue.

Autres remarques

Sales restrictions may apply.

Produit(s) apparenté(s)

Réf. du produit
Description
Tarif

1067001

Betamethasone acetate, United States Pharmacopeia (USP) Reference Standard

1067704

Betamethasone dipropionate, United States Pharmacopeia (USP) Reference Standard

1069007

Betamethasone 17-valerate, United States Pharmacopeia (USP) Reference Standard

1068004

Betamethasone sodium phosphate, United States Pharmacopeia (USP) Reference Standard

B1055000

Betamethasone 21-valerate, European Pharmacopoeia (EP) Reference Standard

B1054000

Betamethasone 17-valerate, European Pharmacopoeia (EP) Reference Standard

B1000000

Betamethasone, European Pharmacopoeia (EP) Reference Standard

B1030000

Betamethasone acetate, European Pharmacopoeia (EP) Reference Standard

B1040000

Betamethasone dipropionate, European Pharmacopoeia (EP) Reference Standard

B1045000

Betamethasone sodium phosphate, European Pharmacopoeia (EP) Reference Standard

Y0001065

Betamethasone valerate impurity mixture, European Pharmacopoeia (EP) Reference Standard

PHR1398

Betamethasone, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1399

Betamethasone Dipropionate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001416

Betamethasone dipropionate for peak identification, European Pharmacopoeia (EP) Reference Standard

1066009

Betamethasone, United States Pharmacopeia (USP) Reference Standard

1069018

Betamethasone Valerate Related Compound A, United States Pharmacopeia (USP) Reference Standard

1067307

Betamethasone benzoate, United States Pharmacopeia (USP) Reference Standard

PHR1779

Betamethasone Acetate, Pharmaceutical Secondary Standard; Certified Reference Material

PHR1780

Betamethasone 17-valerate, Pharmaceutical Secondary Standard; Certified Reference Material

Y0001925

Betamethasone dipropionate for system suitability A, European Pharmacopoeia (EP) Reference Standard

BP041

Betamethasone sodium phosphate, British Pharmacopoeia (BP) Reference Standard

BP575

Betamethasone, British Pharmacopoeia (BP) Reference Standard

BP043

Betamethasone 21-valerate, British Pharmacopoeia (BP) Reference Standard

BP042

Betamethasone 17-valerate, British Pharmacopoeia (BP) Reference Standard

1067045

Betamethasone Acetate Related Compound D, United States Pharmacopeia (USP) Reference Standard

1067726

Betamethasone Dipropionate Related Compound B, United States Pharmacopeia (USP) Reference Standard

1067737

Betamethasone Dipropionate Related Compound C, United States Pharmacopeia (USP) Reference Standard

1067760

Betamethasone Dipropionate Related Compound F , United States Pharmacopeia (USP) Reference Standard

1067781

Betamethasone dipropionate Related Compound H, United States Pharmacopeia (USP) Reference Standard

Pictogrammes

Health hazard
GHS08

Mention d'avertissement

Danger

Mentions de danger

H360FD,H373

Classification des risques

Repr. 1B - STOT RE 2

Code de la classe de stockage

6.1C - Combustible acute toxic Cat.3 / toxic compounds or compounds which causing chronic effects

Classe de danger pour l'eau (WGK)

WGK 2

Faites votre choix parmi les versions les plus récentes :

Certificats d'analyse (COA)

Lot/Batch Number

Désolés, nous n'avons pas de COA pour ce produit disponible en ligne pour le moment.

Si vous avez besoin d'assistance, veuillez contacter Service Clients

Déjà en possession de ce produit ?

Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.

Consulter la Bibliothèque de documents

Yasutomo Fujii et al.
Archives of dermatological research, 302(9), 645-652 (2010-06-16)
Topical glucocorticoids, widely used for the treatment of a variety of dermatitises, are known to exacerbate atopic dermatitis after long-term or inappropriate use. In some animal models, topical glucocorticoids augment the allergic cutaneous inflammation after repeated application, suggesting a relationship
Annabel Maruani et al.
International journal of pharmaceutics, 395(1-2), 84-90 (2010-05-18)
Topical steroids are efficient in vasoconstriction potential, which is linked to their anti-inflammatory activity. Low-frequency ultrasound (US) applied on the skin (sonophoresis) may enhance the transdermal transport of various steroids. We aimed to assess, in a simple, blinded, randomized controlled
Feray Soyupek et al.
Rheumatology international, 32(10), 3229-3234 (2011-11-01)
Firstly, we aimed to determine the effectiveness of various treatment modalities using ultrasonography (US), and secondly, we aimed to assess the correlations between the ultrasonographic findings and electrophysiological tests, symptom severity, functional status and physical findings. 74 hands of 47
V Salini et al.
International journal of immunopathology and pharmacology, 24(1), 211-216 (2011-04-19)
Relapses are frequently observed in subjects with chronic tendinopathies. Corticosteroid injections are usually performed with positive results, but are uncomfortable for the patient and not free from side effects. The aim of this pilot study is to evaluate the short-term
Jin Zhang et al.
Journal of pharmaceutical sciences, 100(3), 896-903 (2010-09-15)
Corticosteroids are therapeutic agents widely used in the pharmacological treatment of skin diseases such as eczema or psoriasis. Unfortunately, their use is restricted by the side effects that frequently occur at the systemic level. The goal of the research described
Afficher tous les articles scientifiques apparentés

Notre équipe de scientifiques dispose d'une expérience dans tous les secteurs de la recherche, notamment en sciences de la vie, science des matériaux, synthèse chimique, chromatographie, analyse et dans de nombreux autres domaines..

Contacter notre Service technique